Agreed.
The discussion should not be "what are the odds Zan's cardioprotective properties will be replicated from the lab and in the clinic?". The discussion should be "what are the odds the complete absence of cardiotoxicity observed at Sheba 2.0 was not a result of Zan's cardioprotective properties?".
15 evaluable patients, no observed cardiotoxicity, despite 4 instances of elevated troponin levels. This completely alters the value proposition.
Cardioprotection thread, page-864
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.68 |
Change
-0.030(1.75%) |
Mkt cap ! $286.2M | |||
| Open | High | Low | Value | Volume |
| $1.73 | $1.73 | $1.68 | $119.9K | 70.42K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3012 | $1.66 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.70 | 6382 | 1 |
View Market Depth
| Last trade - 15.07pm 03/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |